Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-D Report: Multicriteria Decision Analysis.

Barbhaiya M, Zuily S, Amigo MC, Andrade D, Avcin T, Bertolaccini ML, Branch DW, Costedoat-Chalumeau N, Crowther M, Ramires de Jesus G, Devreese KMJ, Frances C, Garcia D, Gómez-Puerta JA, Guillemin F, Levine SR, Levy RA, Lockshin MD, Ortel TL, Petri M, Sanna G, Sciascia S, Seshan SV, Tektonidou MG, Wahl D, Willis R, Yelnik C, Hendry A, Naden R, Costenbader K, Erkan D, ACR/EULAR APS Classification Criteria Collaborators

Open source

DOI: 10.1002/acr.25415
Published: 2024 Dec
Container: Arthritis care & research
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/acr.25415,
  title = {Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-D Report: Multicriteria Decision Analysis.},
  author = {Barbhaiya M and Zuily S and Amigo MC and Andrade D and Avcin T and Bertolaccini ML and Branch DW and Costedoat-Chalumeau N and Crowther M and Ramires de Jesus G and Devreese KMJ and Frances C and Garcia D and Gómez-Puerta JA and Guillemin F and Levine SR and Levy RA and Lockshin MD and Ortel TL and Petri M and Sanna G and Sciascia S and Seshan SV and Tektonidou MG and Wahl D and Willis R and Yelnik C and Hendry A and Naden R and Costenbader K and Erkan D and ACR/EULAR APS Classification Criteria Collaborators},
  year = {2024},
  journal = {Arthritis care \& research},
  doi = {10.1002/acr.25415},
  url = {https://doi.org/10.1002/acr.25415}
}

RIS

TY  - JOUR
TI  - Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-D Report: Multicriteria Decision Analysis.
AU  - Barbhaiya M
AU  - Zuily S
AU  - Amigo MC
AU  - Andrade D
AU  - Avcin T
AU  - Bertolaccini ML
AU  - Branch DW
AU  - Costedoat-Chalumeau N
AU  - Crowther M
AU  - Ramires de Jesus G
AU  - Devreese KMJ
AU  - Frances C
AU  - Garcia D
AU  - Gómez-Puerta JA
AU  - Guillemin F
AU  - Levine SR
AU  - Levy RA
AU  - Lockshin MD
AU  - Ortel TL
AU  - Petri M
AU  - Sanna G
AU  - Sciascia S
AU  - Seshan SV
AU  - Tektonidou MG
AU  - Wahl D
AU  - Willis R
AU  - Yelnik C
AU  - Hendry A
AU  - Naden R
AU  - Costenbader K
AU  - Erkan D
AU  - ACR/EULAR APS Classification Criteria Collaborators
PY  - 2024
JO  - Arthritis care & research
DO  - 10.1002/acr.25415
UR  - https://doi.org/10.1002/acr.25415
ER  -

APA

M, B., S, Z., MC, A., D, A., T, A., ML, B., DW, B., N, C., M, C., G, R. D. J., KMJ, D., C, F., D, G., JA, G., F, G., SR, L., RA, L., MD, L., TL, O., M, P., G, S., S, S., SV, S., MG, T., D, W., R, W., C, Y., A, H., R, N., K, C., D, E., & Collaborators, A. A. C. C. (2024). Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-D Report: Multicriteria Decision Analysis.. Arthritis care & research. https://doi.org/10.1002/acr.25415

Source records

pubmed · retrieved 2026-09-25T01:57:06.139Z